1. Home
  2. NPFD vs REPL Comparison

NPFD vs REPL Comparison

Compare NPFD & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Variable Rate Preferred & Income Fund

NPFD

Nuveen Variable Rate Preferred & Income Fund

HOLD

Current Price

$18.73

Market Cap

452.1M

Sector

Finance

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$8.85

Market Cap

407.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NPFD
REPL
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
452.1M
407.1M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
NPFD
REPL
Price
$18.73
$8.85
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$5.67
AVG Volume (30 Days)
52.8K
6.3M
Earning Date
01-01-0001
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.25
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.59
$1.50
52 Week High
$20.12
$13.24

Technical Indicators

Market Signals
Indicator
NPFD
REPL
Relative Strength Index (RSI) 40.46 64.89
Support Level $18.51 $8.24
Resistance Level $19.37 $9.01
Average True Range (ATR) 0.20 0.88
MACD -0.02 0.07
Stochastic Oscillator 32.27 69.17

Price Performance

Historical Comparison
NPFD
REPL

About NPFD Nuveen Variable Rate Preferred & Income Fund

Nuveen Variable Rate Preferred&Income is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The fund invests a majority of its assets in variable-rate preferred securities and other variable-rate income-producing securities. The rest of its investments can be made in contingent capital securities or contingent convertible securities, convertible securities, corporate debt securities, U.S. government securities, residential and commercial mortgage-backed securities, fixed-rate preferred securities, senior loans and loan participations and assignments, sovereign debt instruments, debt securities issued by supranational agencies, and/or taxable and tax-exempt municipal bonds.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: